



Development of Novel Targeted and Immune Therapies for Lung Cancer



(Harvard Medical School)

2018 9 17 14:30

205

2013

Dana-Farber Cancer Institute

, 2014

Dr. Kwok-Kin Wong

合

EGFR, KRAS

HER2

Clinical Cancer Research, Cancer Immunology Research, Cancer Discovery, Nature Medicine, Theranostics Cancer Research

Selected Publications

1. Liu S*, Li S*, Hai J, Wang X, Chen T, Quinn MM, et al. Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. *Clin Cancer Res*. 2018 Jun 1;24(11):2594-2604. (Equal contribution)
2. Li S*, Liu S*, Deng J, Akbay EA, Hai J, Ambrogio C, et al. Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. *Clin Cancer Res*. 2018 Jun 26. (Equal contribution)
3. Adeegbe DO*, Liu S*, Hattersley MM, Bowden M, Zhou CW, Li S, et al. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. *Cancer Immunol Res*. 2018 Aug 7. (Equal contribution)
4. Li C*, Liu S*, Yan R*, Han N, Wong KK, Li L. CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. *Theranostics*. 2017 Jan 1;7(1):67-80 (Equal contribution)
5. Yang Z*, Liu S*, Zhu M, Zhang H, Wang J, Xu Q, et al. PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway. *Sci Rep*. 2016 Feb 26;6:22090. (Equal contribution)

欢迎各位大师莅临指导！

主办：浙江大学医学院